+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
25 Jul 2017

Case Study: Pricing of Biosimilar – A present Trend in US market

/
Posted By
/
Comments0

We will look into a case study to understand present market trends as far as the pricing of the biosimilars are considered in US market.

Case of Pricing of Multiple Remicade Biosimilar

Innovator Biologic
Johnson & Johnson’s rheumatoid arthritis drug Remicade
Remicade had U.S. sales of $4.8 billion last year.

Biosimilar 1

  • Inflectra By Pfizer
  • 2016 Inflectra launched at 15% discount to J&J’s Remicade Price and later part discount extended to 20%.
Inflectra15%

Biosimilar 2

  • Renflexis by Merck and South Korea’s Samsung Bioepis.
  • Expected to enter into the market in July 2017.
  • Got US biosimilar approval in April 2017.

Question here is what should be the pricing strategy for the Remicade Biosimilar 2 – Renflexis.
Renflexis35%

It may be expected to enter the market with 35% economical to Remicade Price.

Learn more about the biopharmaceutical and Biosimilar Strategic Management >> Learn More

Market Scenario:

  • Merck sells the branded version of Remicade outside the United States. In Europe, it is already facing competition from biosimilar Remicade and cheaper versions of other medicines in the class.
  • As with generic medicines, once multiple biosimilars of a drug become available prices are expected to drop more quickly.
  • J&J offers a variety of discounts and rebates off the list price of Remicade, giving it an average sales price of $808.87 per 100mg vial.
  • J&J’s Janssen unit sought a preliminary or permanent U.S. injunction to block the Bioepis version, arguing that it infringed three of its patents. A hearing for the lawsuit has yet to be scheduled.
  • Renflexis is the first biosimilar available in the United States under a global biosimilars agreement between Merck and Samsung Bioepis, a unit of Samsung BioLogics.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.